TP53 and neoplasm: The debate continued until 2004, when O’Shea et al. identified that ONYX-015’s tumor specificity was linked to the mechanism of late viral RNA transport within cancer cells rather than p53 presence, underscoring the complexity of viral oncolysis in cancer treatment [45].